Hadassah Medical Center, Division of Hematology, Jerusalem, Israel.
Exp Hematol. 2012 Sep;40(9):698-704.e2. doi: 10.1016/j.exphem.2012.05.009. Epub 2012 Jun 1.
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) have traditionally been considered as two distinct entities. However, there are rare reports of patients that, over time, develop both diseases. It remains unresolved whether the origin of the two diseases is from the same clone. In this study, we attempted to retrospectively investigate the clinical and molecular aspects of patients who developed both lymphomas. The rearranged immunoglobulin heavy-chain variable region genes from both diagnoses were compared to each other. Twenty-six patients presented with both diagnoses. Twelve had HL as the primary disorder ("HL first" group) and the majority of these (75%) presented with aggressive lymphoma as the second lymphoma. In contrast, in the 11 patients for whom NHL was the primary disorder ("NHL first" group), this was usually (82%) of low-grade histology. Three patients were diagnosed concurrently with both diseases. Mean age at first diagnosis was higher (p = 0.037) in the NHL first group (56.1 years) than in the HL first group (40 years). Mean time between diagnoses was longer (p = 0.026) in the HL first group (9 years) than in the NHL first group (5 years). For 11 patients, diagnostic samples were available for molecular analyses from both diagnoses of HL and NHL. In 6 of these 11 patients, gene rearrangement studies were informative. No patient had the same gene rearrangement identified in both diseases. It seems that development of HL and NHL in one patient, at different time points, reflects, in many cases, separate biologic diseases.
霍奇金淋巴瘤 (HL) 和非霍奇金淋巴瘤 (NHL) 传统上被认为是两种截然不同的实体。然而,有罕见的报道称,一些患者随着时间的推移会同时患上这两种疾病。目前仍不清楚这两种疾病的起源是否来自同一克隆。在这项研究中,我们试图回顾性调查同时患有两种淋巴瘤的患者的临床和分子方面。比较了来自两种诊断的重排免疫球蛋白重链可变区基因。26 名患者同时被诊断出两种疾病。12 名患者以 HL 为首发疾病(“HL 首发”组),其中大多数(75%)以侵袭性淋巴瘤为第二种淋巴瘤。相比之下,在以 NHL 为首发疾病的 11 名患者(“NHL 首发”组)中,这通常是(82%)低级别组织学。有 3 名患者同时被诊断出两种疾病。首次诊断时的平均年龄(p = 0.037)在 NHL 首发组(56.1 岁)高于 HL 首发组(40 岁)。HL 首发组(9 年)两次诊断之间的平均时间间隔(p = 0.026)长于 NHL 首发组(5 年)。对于 11 名患者,HL 和 NHL 的两次诊断均有可供分子分析的诊断样本。在这 11 名患者中的 6 名中,基因重排研究具有信息性。没有患者在两种疾病中都发现相同的基因重排。似乎在不同时间点在同一患者中同时发生 HL 和 NHL 反映了许多情况下是两种不同的生物学疾病。